IP Library Granted Patent US 8,541,474
Granted Patent B2
US 8,541,474 · App. 13/241,731 · Granted Sep 24, 2013

N,N-dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same

Inventors: Sung Wuk Kim (Gyeonggi-do, KR); Sung Soo Jun (Gyeongi-do, KR); Young Gwan Jo (Daejeon, KR); Ja Seong Koo (Daejeon, KR); Young Woong Kim (Daejeon, KR)
Assignee: Hanall Biopharma Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,541,474
App. No.
13/241,731
Granted
Sep 24, 2013
Kind
B2
Abstract

The present invention relates to N,N-dimethyl imidodicarbonimidic diamide acetate, a method of preparing the same and a pharmaceutical composition comprising the same, and more particularly, to N,N-dimethyl imidodicarbonimidic diamide acetate which is a crystalline acid addition salt prepared by reacting N,N-dimethyl imidodicarbonimidic diamide with acetic acid, and which is very effective as a therapeutic agent for treating metabolic syndromes that glycosuria and diabetes mellitus, obesity, hyperlipidemia, fatty liver, coronary heart disease, osteoporosis, polycystic ovarian syndrome, a cancer depleted of gene P53, etc. are complexly occurred; treating diabetes mellitus and preventing its complication; and treating a cancer and preventing myalgia, muscle cell cytotoxicity and rhabdomyolysis, etc. since the acid addition salt is excellent in physicochemical properties such as solubility, stability, non-hygroscopicity, anti-adhering property, etc., and low toxicity, a method of preparing the same and a pharmaceutical composition comprising the same.

Claims (3)

1. A method of treating or preventing obesity, which comprises administrating to a patient an effective amount of a pharmaceutical composition containing a metformin acetate of formula 1 as an active ingredient

2. The method of claim 1 , wherein the metformin acetate is orally administrated in amount of 50 to 3,000 mg per a day.

3. The method of claim 1 , wherein the metformin acetate is anhydrous metformin acetate.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2013
From: KIM, SUNG WUK; JUN, SUNG SOO; JO, YOUNG GWAN; KOO, JA SEONG; KIM, YOUNG WOONG
To: HANALL BIOPHARMA CO., LTD.
Reel/Frame 030727/0366 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2011
From: KIM, SUNG WUK; JUN, SUNG SOO; JO, YOUNG GWAN; KOO, JA SEONG; KIM, YOUNG WOONG
To: HANALL PHARMACEUTICAL COMPANY, LTD.
Reel/Frame 027077/0917 →
CHANGE OF NAME Recorded Oct 18, 2011
From: HANALL PHARMACEUTICAL COMPANY, LTD.
To: HANALL BIOPHARMA CO., LTD.
Reel/Frame 027081/0442 →
Priority Claims (1)
KR 1-2007-0008835 · Jan 29, 2007 · national
Continuity (2)
Continuation 12524695
Related Publication 20120010287A1 · Jan 12, 2012